NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS. The results of the clinical studies confirm the pharmacologic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1556 |
| _version_ | 1797841728307200000 |
|---|---|
| author | S. N. AVDEEV |
| author_facet | S. N. AVDEEV |
| author_sort | S. N. AVDEEV |
| collection | DOAJ |
| description | The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS. The results of the clinical studies confirm the pharmacological concept of synergistic potentiation of the bronchodilator effect by using medications with different mechanisms of action, which LABA and LAACD are. It is important that the achievement of additional therapeutic effect is possible without increasing the risk of adverse effects. All this is the basis for the conclusion that the joint indication of indacaterol and glycopyrrolate can lead to optimization and maximization of bronchodilatation of many COPD patients who didn’t achieve adequate improvement of bronchial patency with the use of only one bronchodilator. Combination therapy with indacaterol and glycopyrronium (drug Ultipro® Brizhaler®, Novartis Pharma) results in significant improvement of clinical symptoms, pulmonary function, quality of life and decrease of exacerbations in patients with COPD. |
| first_indexed | 2024-04-09T16:36:01Z |
| format | Article |
| id | doaj.art-dbb3a4cf50b8495dae12b710fa374e39 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:36:01Z |
| publishDate | 2016-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-dbb3a4cf50b8495dae12b710fa374e392023-04-23T06:56:54ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902016-12-01015111610.21518/2079-701X-2016-15-11-161550NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPYS. N. AVDEEV0Scientific and Research Institute of Pulmonology of the Federal Medical and Biological Agency of RussiaThe therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS. The results of the clinical studies confirm the pharmacological concept of synergistic potentiation of the bronchodilator effect by using medications with different mechanisms of action, which LABA and LAACD are. It is important that the achievement of additional therapeutic effect is possible without increasing the risk of adverse effects. All this is the basis for the conclusion that the joint indication of indacaterol and glycopyrrolate can lead to optimization and maximization of bronchodilatation of many COPD patients who didn’t achieve adequate improvement of bronchial patency with the use of only one bronchodilator. Combination therapy with indacaterol and glycopyrronium (drug Ultipro® Brizhaler®, Novartis Pharma) results in significant improvement of clinical symptoms, pulmonary function, quality of life and decrease of exacerbations in patients with COPD.https://www.med-sovet.pro/jour/article/view/1556copdbronchodilatorsfixed combination slong-acting anticholinergicslong-acting β2-agonistsindacaterolglycopyrronium bromide |
| spellingShingle | S. N. AVDEEV NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY Медицинский совет copd bronchodilators fixed combination s long-acting anticholinergics long-acting β2-agonists indacaterol glycopyrronium bromide |
| title | NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY |
| title_full | NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY |
| title_fullStr | NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY |
| title_full_unstemmed | NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY |
| title_short | NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY |
| title_sort | new fixed combination of long acting anticholinergic glycopyrronium bromide and β2 agonist of indacaterol prospects of cobd therapy |
| topic | copd bronchodilators fixed combination s long-acting anticholinergics long-acting β2-agonists indacaterol glycopyrronium bromide |
| url | https://www.med-sovet.pro/jour/article/view/1556 |
| work_keys_str_mv | AT snavdeev newfixedcombinationoflongactinganticholinergicglycopyrroniumbromideandb2agonistofindacaterolprospectsofcobdtherapy |